
About Neogen Chemicals
Neogen Chemicals is a publicly listed company based in Thane (India) founded in 1991 by Haridas T Kanan. Specialty chemicals are manufactured for diverse applications worldwide. The company has 965 employees. Neogen Chemicals has completed 3 acquisitions, including Buli Chemicals India, CAPInnoVet and Paw Print Genetics. Its Indian entity Neogen Chemicals Limited reported revenue of βΉ868 Cr. Neogen Chemicals offers products and services including Bromine Based Compounds, Grignard Reagents, Lithium Salts, and Advance Intermediates. Its focus areas include Chemicals and Materials, Diversified Chemicals and Speciality Chemicals.
Company details
Neogen Chemicals was established in 1991 in Thane, India, focusing on the production of specialty chemicals. Operations center on developing and supplying chemicals for industrial uses across sectors such as agrochemicals, pharmaceuticals, and electronics. The company is directed by founder Haridas T Kanan as Managing Director, alongside Harin Haridas Kanani in the same role. Activities are based primarily in India, with distribution extending to international markets.
- Headquarters Thane, India
- Employees 965
- Founders Haridas T Kanan
- Stage Public
- SectorsChemicals & Materials
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website neogenchem.com
- Social LinkedIn
- Legal Name Neogen Chemicals Ltd.
- Market Cap₹6,795 Cr
NEOGEN · NSE
- Share Price₹2,171.40
-3.99% today
- Revenue₹862 Cr
FY 2025-26 · +10.9% YoY
- EBITDA₹137 Cr
Margin 15.9%
- Net Profit₹28.75 Cr
FY 2025-26 · -33.6% YoY
- P/E (TTM)191.9x
P/B 4.3x
- ROE3.6%
ROCE 6.4%
- Debt / Equity1.24
Interest cover 68.4x
- Employee Count965
- Investments & AcquisitionsBuli Chemicals India
& 2 more
Associated legal entities of Neogen Chemicals
Neogen Chemicals operates through Neogen Chemicals Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Neogen Chemicals Limited Listed CIN L24200MH1989PLC050919 | Active | 07 Mar 1989 | Thane, Maharashtra | ₹868 Cr | 601 | 10 | View details |
Products & Services of Neogen Chemicals
Neogen Chemicals offers a comprehensive portfolio of products and services, including Bromine Based Compounds, Grignard Reagents, Lithium Salts, and Advance Intermediates.
Compounds for chemical synthesis and industrial use.
Reagents used in organic synthesis processes.
Salts for battery and chemical applications.
Intermediates for pharmaceutical and specialty uses.
Board of directors of Neogen Chemicals Limited (Neogen Chemicals)
Neogen Chemicals Limited is the primary company behind Neogen Chemicals. The board of Neogen Chemicals Limited currently have 8 directors; the longest-serving is Harin Haridas Kanani, appointed in 2013. 11 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Harin Haridas Kanani DIN 05136947 | Managing Director | 15 Jul 2013 | 13 yrs 3 mo | Neogen Chemicals Limited |
| Shyamsunder Radheshyam Upadhyay DIN 07274873 | Whole-time director | 27 Jul 2015 | 11 yrs 3 mo | Neogen Chemicals Limited |
| Anurag Surana DIN 00006665 | Director | 15 May 2017 | 9 yrs 5 mo | Neogen Chemicals Limited |
| Avi Kersi Sabavala DIN 08246256 | Director | 06 Oct 2018 | 8 yrs | Neogen Chemicals Limited |
| Ranjan Kumar Malik DIN 08221989 | Director | 06 Oct 2018 | 8 yrs | Neogen Chemicals Limited |
| Rajeshkumar Babulal Shah DIN 10729851 | Director | 07 Aug 2024 | 2 yrs 2 mo | Neogen Chemicals Limited |
| Manoj Kumar Pati DIN 06971840 | Director | 26 Oct 2024 | 2 yrs | Neogen Chemicals Limited |
| Triplicane Commandoor Narasimhan Saikrishnan DIN 10498119 | Director | 01 Oct 2025 | 1 yr 1 mo | Neogen Chemicals Limited |
People of Neogen Chemicals
38 people are tracked at Neogen Chemicals (12 in leadership, 6 in board & advisors, 20 in team); the tracked headcount is 965.
| Name | Role | Group |
|---|---|---|
Haridas T Kanan | Founder & Managing Director | Leadership |
| Managing Director | Leadership | |
Ravi Bhensadadiya | General Manager | Leadership |
| Chairman & Managing Director | Leadership | |
| Managing Director | Leadership | |
Kirit Chauhan | Sr. Vice President - HR | Leadership |
Jitendra Kumar Sinha | Vice President | Leadership |
Naresh Bolla | Assistant Vice President | Leadership |
Nikhil Jain | General Manager Finance | Leadership |
Dr Ankur Khant | Assistant General Manager | Leadership |
Rupal Mehta | Sr. General Manager HR | Leadership |
Dr. Ashvin Kumar Upadhyay | Head Of Qc/adl | Leadership |
Hitesh Reshamwala | Independent Director | Board & advisors |
| Non-Executive Director | Board & advisors | |
Sanjay Mehta | Independent Director | Board & advisors |
| Independent Director | Board & advisors | |
| Independent Director | Board & advisors | |
| Whole Time Director | Board & advisors | |
Chintan Tanna | AGM Business Development | Team |
Ankit Kayasth | Senior Executive | Team |
18 more people are available in the full profile.
Complete people profiles for Neogen Chemicals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Neogen Chemicals
Neogen Chemicals is a publicly listed company on the NSE with ticker symbol NEOGEN in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 May 2019
- Listed onBSE: 542665 · NSE: NEOGEN
- Listed entityNeogen Chemicals Ltd.
- Exchange sectorProcess industries
- ISININE136S01016
- Share price₹2,729.10 (+6.2% on the day) · 2026-10-14
- Market capitalisation₹7,713 Cr
- Price to earnings206.1
- EPS (diluted, trailing year)₹13.24
- Dividend yield0.04%
- Volume (last session)574,128
Financials of Neogen Chemicals
Exchange-reported figures of Neogen Chemicals Limited, the listed company behind Neogen Chemicals (NSE: NEOGEN).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 862 | 778 | 691 | 686 | 487 | 336 | 306 |
| Revenue growth | +10.9% | +12.6% | +0.7% | +40.8% | +44.8% | +9.9% | - |
| EBITDA | 137 | 122 | 110 | 112 | 86.59 | 64.36 | 58.06 |
| EBITDA margin | +15.9% | +15.7% | +15.9% | +16.3% | +17.8% | +19.1% | +19.0% |
| Profit before tax | 41.08 | 50.16 | 52.77 | 71.03 | 57.07 | 44.21 | 41.10 |
| Net profit | 28.75 | 43.32 | 35.65 | 49.97 | 44.63 | 31.33 | 28.65 |
| Net profit margin | +3.3% | +5.6% | +5.2% | +7.3% | +9.2% | +9.3% | +9.4% |
| EPS (βΉ) | 10.90 | 13.20 | 13.51 | 20.04 | 17.89 | 13.43 | 12.28 |
| Balance sheet | |||||||
| Total assets | 2,229 | 1,399 | 1,182 | 860 | 676 | 410 | 306 |
| Net worth | 816 | 789 | 760 | 483 | 439 | 183 | 156 |
| Total debt | 1,395 | 597 | 409 | 370 | 229 | 222 | 137 |
| Cash & bank | 4.95 | 4.96 | 12.49 | 20.70 | 45.22 | 1.21 | 1.48 |
| Net working capital | 732 | 669 | 528 | 405 | 299 | 166 | 188 |
| Cash flow | |||||||
| Cash from operations | (231) | 196 | (29.15) | (30.35) | 1.41 | 83.57 | (34.55) |
| Cash from investing | (410) | (317) | (216) | (94.46) | (146) | (135) | (28.63) |
| Cash from financing | 642 | 113 | 237 | 100 | 188 | 50.73 | 62.64 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 250 | 247 | 220 | 209 | 187 | 203 | 201 | 193 |
| Revenue growth (YoY) | +34.0% | +21.6% | +9.2% | +7.9% | +3.8% | - | - | - |
| Other income | 4.06 | 1.01 | 2.20 | 1.98 | 1.23 | 0.64 | 1.14 | 0.84 |
| EBITDA | 48.23 | 43.91 | 31.90 | 29.96 | 31.51 | 22.30 | 34.64 | 34.51 |
| EBITDA margin | +19.3% | +17.8% | +14.5% | +14.4% | +16.9% | +11.0% | +17.2% | +17.8% |
| Depreciation | 8.20 | 7.60 | 6.83 | 7.31 | 5.78 | 6.76 | 7.10 | 7.12 |
| Interest | 20.81 | 21.47 | 21.51 | 19.48 | 12.67 | 12.50 | 13.43 | 12.75 |
| Profit before tax | 23.28 | 15.85 | 5.76 | 5.15 | 14.29 | 3.68 | 15.25 | 15.48 |
| Tax | 6.17 | 4.46 | 2.07 | 1.78 | 4.03 | 1.27 | 5.24 | 4.52 |
| Net profit | 17.11 | 11.39 | 3.69 | 3.37 | 10.26 | 2.41 | 10.01 | 10.96 |
| EPS (βΉ) | 6.29 | 4.32 | 1.40 | 1.28 | 3.89 | 0.91 | 3.80 | 4.15 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 855 | 774 | 701 | 686 | 487 | 336 | 306 |
| Revenue growth | +10.6% | +10.3% | +2.2% | +40.8% | +44.8% | +9.9% | - |
| EBITDA | 151 | 134 | 116 | 112 | 86.59 | 64.36 | 58.06 |
| EBITDA margin | +17.7% | +17.3% | +16.6% | +16.3% | +17.8% | +19.1% | +19.0% |
| Profit before tax | 63.13 | 66.36 | 59.46 | 71.11 | 57.16 | 44.32 | 41.22 |
| Net profit | 45.83 | 57.93 | 41.13 | 50.05 | 44.72 | 31.44 | 28.77 |
| Net profit margin | +5.4% | +7.5% | +5.9% | +7.3% | +9.2% | +9.4% | +9.4% |
| EPS (βΉ) | 17.80 | 18.35 | 15.59 | 20.07 | 17.93 | 13.48 | 12.33 |
| Balance sheet | |||||||
| Total assets | 1,603 | 1,296 | 1,188 | 861 | 676 | 410 | 307 |
| Net worth | 854 | 809 | 766 | 483 | 439 | 183 | 157 |
| Total debt | 736 | 474 | 409 | 370 | 229 | 222 | 137 |
| Cash & bank | 3.05 | 0.48 | 2.30 | 20.70 | 45.22 | 1.21 | 1.48 |
| Net working capital | 719 | 762 | 639 | 406 | 299 | 167 | 189 |
| Cash flow | |||||||
| Cash from operations | (99.20) | 199 | (134) | (30.35) | 1.20 | 83.29 | (34.12) |
| Cash from investing | (35.16) | (188) | (129) | (94.46) | (146) | (134) | (28.88) |
| Cash from financing | 137 | (12.14) | 226 | 100 | 188 | 50.73 | 62.46 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 252 | 249 | 216 | 207 | 185 | 204 | 200 | 193 |
| Revenue growth (YoY) | +36.7% | +22.0% | +7.6% | +7.0% | +4.7% | - | - | - |
| Other income | 7.90 | 3.87 | 4.26 | 4.37 | 3.31 | 2.65 | 2.05 | 2.24 |
| Total expenses | 204 | 203 | 179 | 172 | 150 | 176 | 163 | 157 |
| EBITDA | 48.16 | 45.38 | 36.26 | 34.95 | 34.68 | 27.61 | 37.65 | 36.49 |
| EBITDA margin | +19.1% | +18.3% | +16.8% | +16.9% | +18.8% | +13.6% | +18.8% | +18.9% |
| Depreciation | 6.83 | 6.38 | 5.87 | 6.39 | 4.88 | 6.01 | 6.58 | 6.61 |
| Interest | 23.10 | 22.95 | 22.85 | 20.60 | 14.03 | 16.50 | 13.07 | 12.30 |
| Profit before tax | 26.13 | 19.92 | 11.80 | 12.33 | 19.08 | 7.75 | 20.05 | 19.82 |
| Tax | 6.69 | 5.26 | 3.03 | 3.02 | 4.85 | 2.56 | 5.64 | 4.96 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 250 | 247 | 220 | 209 | 187 | 203 | 201 | 193 |
| Revenue growth (YoY) | +34.0% | +21.6% | +9.2% | +7.9% | +3.8% | - | - | - |
| Other income | 4.06 | 1.01 | 2.20 | 1.98 | 1.23 | 0.64 | 1.14 | 0.84 |
| EBITDA | 48.23 | 43.91 | 31.90 | 29.96 | 31.51 | 22.30 | 34.64 | 34.51 |
| EBITDA margin | +19.3% | +17.8% | +14.5% | +14.4% | +16.9% | +11.0% | +17.2% | +17.8% |
| Depreciation | 8.20 | 7.60 | 6.83 | 7.31 | 5.78 | 6.76 | 7.10 | 7.12 |
| Interest | 20.81 | 21.47 | 21.51 | 19.48 | 12.67 | 12.50 | 13.43 | 12.75 |
| Profit before tax | 23.28 | 15.85 | 5.76 | 5.15 | 14.29 | 3.68 | 15.25 | 15.48 |
| Tax | 6.17 | 4.46 | 2.07 | 1.78 | 4.03 | 1.27 | 5.24 | 4.52 |
| Net profit | 17.11 | 11.39 | 3.69 | 3.37 | 10.26 | 2.41 | 10.01 | 10.96 |
| EPS (βΉ) | 6.29 | 4.32 | 1.40 | 1.28 | 3.89 | 0.91 | 3.80 | 4.15 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 862 | 778 | 691 | 686 | 487 | 336 | 306 |
| Revenue growth | +10.9% | +12.6% | +0.7% | +40.8% | +44.8% | +9.9% | - |
| Other income | 6.42 | 4.21 | 7.65 | 4.55 | 1.25 | 0.52 | 0.21 |
| Total expenses | 725 | 655 | 581 | 575 | 401 | 272 | 248 |
| Employee cost | 124 | 75.49 | 62.00 | 46.82 | 31.50 | 20.07 | 17.25 |
| EBITDA | 137 | 122 | 110 | 112 | 86.59 | 64.36 | 58.06 |
| EBITDA margin | +15.9% | +15.7% | +15.9% | +16.3% | +17.8% | +19.1% | +19.0% |
| Depreciation | 27.52 | 27.79 | 22.87 | 16.20 | 11.69 | 6.90 | 5.24 |
| Interest | 75.11 | 48.50 | 42.06 | 28.94 | 19.08 | 13.77 | 11.93 |
| Profit before tax | 41.08 | 50.16 | 52.77 | 71.03 | 57.07 | 44.21 | 41.10 |
| Tax | 12.33 | 15.33 | 17.12 | 21.06 | 12.44 | 12.88 | 12.45 |
| Net profit | 28.75 | 43.32 | 35.65 | 49.97 | 44.63 | 31.33 | 28.65 |
| Net profit margin | +3.3% | +5.6% | +5.2% | +7.3% | +9.2% | +9.3% | +9.4% |
| EPS (βΉ) | 10.90 | 13.20 | 13.51 | 20.04 | 17.89 | 13.43 | 12.28 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 26.38 | 26.38 | 26.38 | 24.94 | 24.94 | 23.33 | 23.33 |
| Reserves & surplus | 790 | 763 | 734 | 458 | 414 | 160 | 133 |
| Shareholders' funds (net worth) | 816 | 789 | 760 | 483 | 439 | 183 | 156 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 1,330 | 566 | 394 | 362 | 225 | 216 | 137 |
| Unsecured loans | 65.20 | 30.70 | 15.39 | 7.30 | 4.02 | 5.74 | 0.00 |
| Total debt | 1,395 | 597 | 409 | 370 | 229 | 222 | 137 |
| Total liabilities | 2,229 | 1,399 | 1,182 | 860 | 676 | 410 | 306 |
| Assets | |||||||
| Gross block | 568 | 475 | 561 | 390 | 313 | 144 | 120 |
| Net block | 475 | 404 | 496 | 347 | 285 | 127 | 111 |
| Capital work in progress | 857 | 156 | 109 | 35.84 | 10.62 | 115 | 2.69 |
| Investments | 0.45 | 0.45 | 0.45 | 76.81 | 81.73 | 0.75 | 0.60 |
| Inventories | 568 | 309 | 382 | 293 | 195 | 114 | 130 |
| Sundry debtors | 380 | 200 | 282 | 177 | 110 | 78.55 | 75.23 |
| Cash & bank balances | 4.95 | 4.96 | 12.49 | 20.70 | 45.22 | 1.21 | 1.48 |
| Loans & advances | 439 | 486 | 107 | 88.72 | 62.39 | 46.37 | 24.47 |
| Total current assets | 1,393 | 1,000 | 784 | 580 | 412 | 240 | 231 |
| Total current liabilities | 661 | 331 | 256 | 174 | 113 | 74.02 | 43.11 |
| Net working capital | 732 | 669 | 528 | 405 | 299 | 166 | 188 |
| Total assets | 2,229 | 1,399 | 1,182 | 860 | 676 | 410 | 306 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 4.96 | 12.50 | 20.70 | 45.22 | 1.21 | 1.48 | 2.02 |
| Net cash from operating activities | (231) | 196 | (29.15) | (30.35) | 1.41 | 83.57 | (34.55) |
| Net cash from investing activities | (410) | (317) | (216) | (94.46) | (146) | (135) | (28.63) |
| Net cash from financing activities | 642 | 113 | 237 | 100 | 188 | 50.73 | 62.64 |
| Net change in cash | (0.03) | (7.54) | (8.20) | (24.52) | 44.01 | (0.27) | (0.54) |
| Closing cash | 4.95 | 4.96 | 12.49 | 20.70 | 45.22 | 1.21 | 1.48 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +10.9% | +12.6% | +0.7% | +40.8% | +44.8% | +9.9% | - |
| EBITDA growth | +12.3% | +11.1% | -1.4% | +28.9% | +34.5% | +10.9% | - |
| PBT growth | -18.1% | -5.0% | -25.7% | +24.5% | +29.1% | +7.6% | +40.5% |
| Net income growth | -33.6% | +21.5% | -28.7% | +12.0% | +42.5% | +9.4% | - |
| Revenue CAGR (3Y) | +7.9% | +16.9% | +27.1% | +30.9% | +26.8% | +27.8% | +40.6% |
| EBITDA CAGR (3Y) | +7.1% | +12.2% | +19.6% | +24.3% | +25.9% | +30.4% | +42.7% |
| Profitability & leverage | |||||||
| Net income margin | +3.3% | +4.5% | +5.2% | +7.3% | +9.2% | +9.3% | +9.4% |
| Return on capital employed | +6.4% | +8.7% | +9.3% | +13.0% | +14.0% | +16.2% | +21.2% |
| Return on net worth | +3.6% | +5.6% | +5.7% | +10.8% | +14.3% | +18.5% | +25.3% |
| Debt / equity | 1.24 | 0.65 | 0.63 | 0.65 | 0.72 | 1.06 | 1.03 |
| Long-term debt / equity | 0.66 | 0.21 | 0.22 | 0.28 | 0.39 | 0.44 | 0.29 |
| Interest cover | 68.42 | 51.35 | 48.25 | 30.33 | 25.47 | 23.96 | 22.59 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.65 | 1.50 | 1.45 | 1.95 | 2.13 | 3.04 | 3.34 |
| Inventory turnover | 1.96 | 2.25 | 2.05 | 2.81 | 3.16 | 3.29 | 3.44 |
| Debtors turnover | 2.97 | 3.23 | 3.01 | 4.78 | 5.18 | 5.21 | 5.12 |
| EPS (βΉ) | 10.90 | 13.20 | 13.51 | 20.04 | 17.89 | 13.43 | 12.28 |
| Dividend per share (βΉ) | 2.00 | 1.00 | 2.00 | 3.00 | 2.75 | 2.25 | 2.00 |
| Book value per share (βΉ) | 309.43 | 299.24 | 288.21 | 193.47 | 176.12 | 78.44 | 66.96 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 252 | 249 | 216 | 207 | 185 | 204 | 200 | 193 |
| Revenue growth (YoY) | +36.7% | +22.0% | +7.6% | +7.0% | +4.7% | - | - | - |
| Other income | 7.90 | 3.87 | 4.26 | 4.37 | 3.31 | 2.65 | 2.05 | 2.24 |
| Total expenses | 204 | 203 | 179 | 172 | 150 | 176 | 163 | 157 |
| EBITDA | 48.16 | 45.38 | 36.26 | 34.95 | 34.68 | 27.61 | 37.65 | 36.49 |
| EBITDA margin | +19.1% | +18.3% | +16.8% | +16.9% | +18.8% | +13.6% | +18.8% | +18.9% |
| Depreciation | 6.83 | 6.38 | 5.87 | 6.39 | 4.88 | 6.01 | 6.58 | 6.61 |
| Interest | 23.10 | 22.95 | 22.85 | 20.60 | 14.03 | 16.50 | 13.07 | 12.30 |
| Profit before tax | 26.13 | 19.92 | 11.80 | 12.33 | 19.08 | 7.75 | 20.05 | 19.82 |
| Tax | 6.69 | 5.26 | 3.03 | 3.02 | 4.85 | 2.56 | 5.64 | 4.96 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 855 | 774 | 701 | 686 | 487 | 336 | 306 |
| Revenue growth | +10.6% | +10.3% | +2.2% | +40.8% | +44.8% | +9.9% | - |
| Other income | 15.82 | 9.76 | 8.08 | 4.63 | 1.34 | 0.63 | 0.33 |
| Total expenses | 704 | 640 | 585 | 575 | 401 | 272 | 248 |
| Employee cost | 77.72 | 58.29 | 57.32 | 46.82 | 31.50 | 20.07 | 17.25 |
| EBITDA | 151 | 134 | 116 | 112 | 86.59 | 64.36 | 58.06 |
| EBITDA margin | +17.7% | +17.3% | +16.6% | +16.3% | +17.8% | +19.1% | +19.0% |
| Depreciation | 23.53 | 25.59 | 22.82 | 16.20 | 11.69 | 6.90 | 5.24 |
| Interest | 80.42 | 51.38 | 42.00 | 28.94 | 19.08 | 13.77 | 11.93 |
| Profit before tax | 63.13 | 66.36 | 59.46 | 71.11 | 57.16 | 44.32 | 41.22 |
| Tax | 16.17 | 17.95 | 18.33 | 21.06 | 12.44 | 12.88 | 12.45 |
| Net profit | 45.83 | 57.93 | 41.13 | 50.05 | 44.72 | 31.44 | 28.77 |
| Net profit margin | +5.4% | +7.5% | +5.9% | +7.3% | +9.2% | +9.4% | +9.4% |
| EPS (βΉ) | 17.80 | 18.35 | 15.59 | 20.07 | 17.93 | 13.48 | 12.33 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 26.38 | 26.38 | 26.38 | 24.94 | 24.94 | 23.33 | 23.33 |
| Reserves & surplus | 827 | 782 | 740 | 458 | 414 | 160 | 133 |
| Shareholders' funds (net worth) | 854 | 809 | 766 | 483 | 439 | 183 | 157 |
| Secured loans | 671 | 444 | 394 | 362 | 225 | 216 | 137 |
| Unsecured loans | 64.26 | 30.70 | 15.40 | 7.30 | 4.02 | 5.74 | 0.00 |
| Total debt | 736 | 474 | 409 | 370 | 229 | 222 | 137 |
| Total liabilities | 1,603 | 1,296 | 1,188 | 861 | 676 | 410 | 307 |
| Assets | |||||||
| Gross block | 384 | 299 | 428 | 390 | 313 | 144 | 119 |
| Net block | 294 | 228 | 361 | 347 | 285 | 127 | 111 |
| Capital work in progress | 161 | 27.53 | 56.10 | 35.84 | 10.62 | 115 | 2.69 |
| Investments | 307 | 193 | 5.45 | 76.51 | 81.21 | 0.45 | 0.45 |
| Inventories | 552 | 306 | 382 | 293 | 195 | 114 | 130 |
| Sundry debtors | 357 | 199 | 282 | 177 | 110 | 78.55 | 75.23 |
| Cash & bank balances | 3.05 | 0.48 | 2.30 | 20.70 | 45.22 | 1.21 | 1.48 |
| Loans & advances | 360 | 561 | 165 | 89.12 | 62.99 | 46.78 | 25.11 |
| Total current assets | 1,271 | 1,066 | 832 | 580 | 412 | 241 | 232 |
| Total current liabilities | 553 | 304 | 193 | 174 | 113 | 74.02 | 43.11 |
| Net working capital | 719 | 762 | 639 | 406 | 299 | 167 | 189 |
| Total assets | 1,603 | 1,296 | 1,188 | 861 | 676 | 410 | 307 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.48 | 2.30 | 38.99 | 45.22 | 1.21 | 1.48 | 2.02 |
| Net cash from operating activities | (99.20) | 199 | (134) | (30.35) | 1.20 | 83.29 | (34.12) |
| Net cash from investing activities | (35.16) | (188) | (129) | (94.46) | (146) | (134) | (28.88) |
| Net cash from financing activities | 137 | (12.14) | 226 | 100 | 188 | 50.73 | 62.46 |
| Net change in cash | 2.56 | (1.82) | (36.69) | (24.52) | 44.01 | (0.27) | (0.54) |
| Closing cash | 3.05 | 0.48 | 2.30 | 20.70 | 45.22 | 1.21 | 1.48 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +10.6% | +10.3% | +2.2% | +40.8% | +44.8% | +9.9% | - |
| EBITDA growth | +13.2% | +15.0% | +4.1% | +28.9% | +34.5% | +10.9% | - |
| PBT growth | -4.9% | +11.6% | -16.4% | +24.4% | +29.0% | +7.5% | +40.4% |
| Net income growth | -20.9% | +40.9% | -17.8% | +11.9% | +42.2% | +9.3% | - |
| Revenue CAGR (3Y) | +7.6% | +16.7% | +27.8% | +30.9% | +26.8% | +27.8% | +40.6% |
| EBITDA CAGR (3Y) | +10.7% | +15.5% | +21.8% | +24.3% | +25.9% | +30.4% | +42.7% |
| Profitability & leverage | |||||||
| Net income margin | +5.5% | +6.3% | +5.9% | +7.3% | +9.2% | +9.4% | +9.4% |
| Return on capital employed | +9.9% | +10.6% | +9.9% | +13.0% | +14.0% | +16.2% | +21.2% |
| Return on net worth | +5.7% | +7.4% | +6.6% | +10.9% | +14.4% | +18.5% | +25.3% |
| Debt / equity | 0.73 | 0.56 | 0.62 | 0.65 | 0.72 | 1.06 | 1.03 |
| Long-term debt / equity | 0.21 | 0.13 | 0.22 | 0.28 | 0.39 | 0.44 | 0.29 |
| Interest cover | 62.96 | 47.58 | 44.98 | 30.33 | 25.47 | 23.96 | 22.59 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.50 | 2.13 | 1.72 | 1.95 | 2.13 | 3.05 | 3.37 |
| Inventory turnover | 1.99 | 2.25 | 2.08 | 2.81 | 3.16 | 3.29 | 3.44 |
| Debtors turnover | 3.08 | 3.21 | 3.05 | 4.78 | 5.18 | 5.21 | 5.12 |
| EPS (βΉ) | 17.80 | 18.35 | 15.59 | 20.07 | 17.93 | 13.48 | 12.33 |
| Dividend per share (βΉ) | 2.00 | 1.00 | 2.00 | 3.00 | 2.75 | 2.25 | 2.00 |
| Book value per share (βΉ) | 323.62 | 306.61 | 290.41 | 193.51 | 176.15 | 78.49 | 67.17 |
Investments & Acquisitions by Neogen Chemicals
Neogen Chemicals has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Buli Chemicals India, CAPInnoVet and Paw Print Genetics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Speciality chemicals and related products are manufactured. | bulichemicalsindia.tcc.mode | Mumbai, India | 2018 | Mar 2023 | β’β’β’β’ | |
Genetic testing for canines is provided to owners and breeders. | pawprintgenetics.com | Spokane, United States | 2012 | Dec 2021 | β’β’β’β’ | |
Pet health products are manufactured by CAPInnoVet in Atlanta. | capinnovet.com | Atlanta, United States | 2014 | Sep 2021 | β’β’β’β’ |
Complete acquisition details for Neogen Chemicals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Neogen Chemicals
5 dated milestones of Neogen Chemicals across 32 years, from founding to its latest funding, stage changes and deals.
- Founded Neogen Chemicals is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires CAPInnoVet.
- Acquisition Acquires Paw Print Genetics.
- Acquisition Acquires Buli Chemicals India.
Web traffic of Neogen Chemicals
The website of Neogen Chemicals (neogenchem.com) receives about 6.5K visits a month.
- Monthly visits6.5K
▲ 67.4% vs previous month
Websites whose visitors overlap most with Neogen Chemicals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| indianchemicalnews.com | 100% | #555,272 | View details | ||
| yashoindustries.com | 97% | 4.3K | #4,362,536 | View details | |
| specchemonline.com | 97% | #1,875,513 | View details | ||
| abscomaterials.com | 97% | #12,344,100 | View details | ||
dge-europe.com | dge-europe.com | 97% | #5,682,776 | β | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 6 similar websites and full traffic analytics for Neogen Chemicals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Core & Diversified Chemicals
3 companies that operate in the same segment as Neogen Chemicals (Core & Diversified Chemicals) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of fertilizers, industrial chemicals, crop nutrition products, and real estate | 1979 | Pune, Maharashtra, India | USD 1.21 B | 1,020 | ||
Specialty chemicals are manufactured through integrated R&D and production processes. | 2023 | Bengaluru, Karnataka, India | USD 72.97 M | USD 2.13 M | ||
Manufactures coal tar and basic industrial chemicals. | 1987 | Kolkata, West Bengal, India | USD 24 M | USD 496.46 M | 2,480 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neogen Chemicals
Complete news archive for Neogen Chemicals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neogen Chemicals
Neogen Chemicals was founded in 1991.
Neogen Chemicals is headquartered in Thane, India. It is registered at Thane, Maharashtra, India.
Neogen Chemicals has 965 employees.
The primary company behind Neogen Chemicals, Neogen Chemicals Limited, reported revenue of βΉ868 Cr for FY 2026, up 11% year on year.
Neogen Chemicals was established in 1991 in Thane, India, focusing on the production of specialty chemicals. Operations center on developing and supplying chemicals for industrial uses across sectors such as agrochemicals, pharmaceuticals, and electronics. The company is directed by founder Haridas T Kanan as Managing Director, alongside Harin Haridas Kanani in the same role. Activities are based primarily in India, with distribution extending to international markets.
Neogen Chemicals offers Bromine Based Compounds, Grignard Reagents, Lithium Salts, and Advance Intermediates.
Yes, Neogen Chemicals is publicly traded on NSE under the ticker symbol NEOGEN.
Neogen Chemicals has made 3 acquisitions, including Buli Chemicals India, CAPInnoVet, and Paw Print Genetics.
Neogen Chemicals operates through Neogen Chemicals Limited.
The legal entities of Neogen Chemicals currently have 10 directors, including Shyamsunder Radheshyam Upadhyay, Unnati Rajesh Kanani, Harin Haridas Kanani and others.
